![]() ![]() 8, 2003, which claims the benefit of U.S. 10/501,187, filed as a National stage of international application No. 10/948,737 is also a continuation-in-part of and claims priority to U.S. 4, 2002, now abandoned, which claims the benefit of U.S. C12Q2600/136- Screening for pharmacological compounds.C12Q2600/112- Disease subtyping, staging or classification.C12Q2600/00- Oligonucleotides characterized by their use.A61K48/00- Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases Gene therapy.A61K- PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES.A61P- SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS.A61- MEDICAL OR VETERINARY SCIENCE HYGIENE.primers or probes for diseases caused by alterations of genetic material for cancer C12Q1/6886- Nucleic acid products used in the analysis of nucleic acids, e.g.primers or probes for diseases caused by alterations of genetic material C12Q1/6883- Nucleic acid products used in the analysis of nucleic acids, e.g.C12Q1/6876- Nucleic acid products used in the analysis of nucleic acids, e.g.C12Q1/68- Measuring or testing processes involving enzymes, nucleic acids or microorganisms Compositions therefor Processes of preparing such compositions involving nucleic acids.C12Q1/00- Measuring or testing processes involving enzymes, nucleic acids or microorganisms Compositions therefor Processes of preparing such compositions.C12Q- MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS COMPOSITIONS OR TEST PAPERS THEREFOR PROCESSES OF PREPARING SUCH COMPOSITIONS CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES.C12- BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION OR GENETIC ENGINEERING.Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) Filing date Publication date Priority claimed from US10/501,187 external-priority patent/US20060141455A1/en Priority claimed from PCT/US2004/015421 external-priority patent/WO2005000087A2/en Application filed by Individual filed Critical Individual Priority to US12/725,341 priority Critical patent/US8221983B2/en Publication of US20100233187A1 publication Critical patent/US20100233187A1/en Priority to US13/491,434 priority patent/US20120308569A1/en Application granted granted Critical Publication of US8221983B2 publication Critical patent/US8221983B2/en Anticipated expiration legal-status Critical Status Expired - Fee Related legal-status Critical Current Links Original Assignee Individual Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) MOLER Filippo Randazzo Christoph Reinhard Julie Sudduth-Klinger Current Assignee (The listed assignees may be inaccurate. Chan Jaime Escobedo Pablo Dominguez Garcia Rhonda Hansen Joerg Kaufmann Giulia C. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Granted Application number US12/725,341 Other versions US8221983B2 Google Patents Gene products differentially expressed in cancerous cellsÄownload PDF Info Publication number US20100233187A1 US20100233187A1 US12/725,341 US72534110A US2010233187A1 US 20100233187 A1 US20100233187 A1 US 20100233187A1 US 72534110 A US72534110 A US 72534110A US 2010233187 A1 US2010233187 A1 US 2010233187A1 Authority US United States Prior art keywords cell gene cancer expression cancerous Prior art date Legal status (The legal status is an assumption and is not a legal conclusion. Google Patents US20100233187A1 - Gene products differentially expressed in cancerous cells US20100233187A1 - Gene products differentially expressed in cancerous cells ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |